ID   PLK1_HUMAN              Reviewed;         603 AA.
AC   P53350; Q15153; Q99746;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Serine/threonine-protein kinase PLK1;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 1;
DE            Short=PLK-1;
DE   AltName: Full=Serine/threonine-protein kinase 13;
DE            Short=STPK13;
GN   Name=PLK1; Synonyms=PLK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8018557;
RA   Hamanaka R., Maloid S., Smith M.R., O'Connell C.D., Longo D.L.,
RA   Ferris D.K.;
RT   "Cloning and characterization of human and murine homologues of the
RT   Drosophila polo serine-threonine kinase.";
RL   Cell Growth Differ. 5:249-257(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7902533; DOI=10.1128/MCB.13.12.7793;
RA   Lake R.J., Jelinek W.R.;
RT   "Cell cycle- and terminal differentiation-associated regulation of the
RT   mouse mRNA encoding a conserved mitotic protein kinase.";
RL   Mol. Cell. Biol. 13:7793-7801(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7962193;
RA   Golsteyn R.M., Schultz S.J., Bartek J., Ziemiecki A., Ried T.,
RA   Nigg E.A.;
RT   "Cell cycle analysis and chromosomal localization of human Plk1, a
RT   putative homologue of the mitotic kinases Drosophila polo and
RT   Saccharomyces cerevisiae Cdc5.";
RL   J. Cell Sci. 107:1509-1517(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8127874; DOI=10.1073/pnas.91.5.1736;
RA   Holtrich U., Wolf G., Braeuninger A., Karn T., Boehme B.,
RA   Ruebsamen-Waigmann H., Strebhardt K.;
RT   "Induction and down-regulation of PLK, a human serine/threonine kinase
RT   expressed in proliferating cells and tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1736-1740(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=7478607;
RA   Brauninger A., Strebhardt K., Rubsamen-Waigmann H.;
RT   "Identification and functional characterization of the human and
RT   murine polo-like kinase (Plk) promoter.";
RL   Oncogene 11:1793-1800(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=9083047; DOI=10.1074/jbc.272.14.9166;
RA   Uchiumi T., Longo D.L., Ferris D.K.;
RT   "Cell cycle regulation of the human polo-like kinase (PLK) promoter.";
RL   J. Biol. Chem. 272:9166-9174(1997).
RN   [8]
RP   FUNCTION IN CENTROSOME MATURATION, AND SUBCELLULAR LOCATION.
RX   PubMed=8991084; DOI=10.1083/jcb.135.6.1701;
RA   Lane H.A., Nigg E.A.;
RT   "Antibody microinjection reveals an essential role for human polo-like
RT   kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.";
RL   J. Cell Biol. 135:1701-1713(1996).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25C.
RX   PubMed=11202906; DOI=10.1016/S0898-6568(00)00080-2;
RA   Roshak A.K., Capper E.A., Imburgia C., Fornwald J., Scott G.,
RA   Marshall L.A.;
RT   "The human polo-like kinase, PLK, regulates cdc2/cyclin B through
RT   phosphorylation and activation of the cdc25C phosphatase.";
RL   Cell. Signal. 12:405-411(2000).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT SER-137 AND THR-210, AND MUTAGENESIS OF
RP   LYS-82; SER-137 AND THR-210.
RX   PubMed=12207013; DOI=10.1074/jbc.M202172200;
RA   Jang Y.-J., Ma S., Terada Y., Erikson R.L.;
RT   "Phosphorylation of threonine 210 and the role of serine 137 in the
RT   regulation of mammalian polo-like kinase.";
RL   J. Biol. Chem. 277:44115-44120(2002).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF CCNB1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LYS-82 AND THR-210.
RX   PubMed=12447691; DOI=10.1038/sj.onc.1206011;
RA   Yuan J., Eckerdt F., Bereiter-Hahn J., Kurunci-Csacsko E.,
RA   Kaufmann M., Strebhardt K.;
RT   "Cooperative phosphorylation including the activity of polo-like
RT   kinase 1 regulates the subcellular localization of cyclin B1.";
RL   Oncogene 21:8282-8292(2002).
RN   [12]
RP   PHOSPHORYLATION AT SER-335.
RX   PubMed=12442251;
RX   DOI=10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y;
RA   Wind M., Kelm O., Nigg E.A., Lehmann W.D.;
RT   "Identification of phosphorylation sites in the polo-like kinases Plx1
RT   and Plk1 by a novel strategy based on element and electrospray high
RT   resolution mass spectrometry.";
RL   Proteomics 2:1516-1523(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF NINL.
RX   PubMed=12852856; DOI=10.1016/S1534-5807(03)00193-X;
RA   Casenghi M., Meraldi P., Weinhart U., Duncan P.I., Korner R.,
RA   Nigg E.A.;
RT   "Polo-like kinase 1 regulates Nlp, a centrosome protein involved in
RT   microtubule nucleation.";
RL   Dev. Cell 5:113-125(2003).
RN   [14]
RP   PHOSPHORYLATION BY STK10.
RX   PubMed=12639966; DOI=10.1074/jbc.M212556200;
RA   Walter S.A., Cutler R.E. Jr., Martinez R., Gishizky M., Hill R.J.;
RT   "Stk10, a new member of the polo-like kinase kinase family highly
RT   expressed in hematopoietic tissue.";
RL   J. Biol. Chem. 278:18221-18228(2003).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF PKMYT1.
RX   PubMed=12738781; DOI=10.1074/jbc.C300126200;
RA   Nakajima H., Toyoshima-Morimoto F., Taniguchi E., Nishida E.;
RT   "Identification of a consensus motif for Plk (Polo-like kinase)
RT   phosphorylation reveals Myt1 as a Plk1 substrate.";
RL   J. Biol. Chem. 278:25277-25280(2003).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF KIF20A, DOMAIN POLO BOX, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH KIF20A.
RX   PubMed=12939256; DOI=10.1083/jcb.200306009;
RA   Neef R., Preisinger C., Sutcliffe J., Kopajtich R., Nigg E.A.,
RA   Mayer T.U., Barr F.A.;
RT   "Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase
RT   1 is required for cytokinesis.";
RL   J. Cell Biol. 162:863-875(2003).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF CCNB1, AND SUBCELLULAR LOCATION.
RX   PubMed=12524548; DOI=10.1038/ncb918;
RA   Jackman M., Lindon C., Nigg E.A., Pines J.;
RT   "Active cyclin B1-Cdk1 first appears on centrosomes in prophase.";
RL   Nat. Cell Biol. 5:143-148(2003).
RN   [18]
RP   FUNCTION, PROTEASOMAL DEGRADATION, DOMAIN D-BOX MOTIF, AND MUTAGENESIS
RP   OF ARG-337 AND LEU-340.
RX   PubMed=14734534; DOI=10.1083/jcb.200309035;
RA   Lindon C., Pines J.;
RT   "Ordered proteolysis in anaphase inactivates Plk1 to contribute to
RT   proper mitotic exit in human cells.";
RL   J. Cell Biol. 164:233-241(2004).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF FBXO5.
RX   PubMed=15469984; DOI=10.1091/mbc.E04-07-0598;
RA   Hansen D.V., Loktev A.V., Ban K.H., Jackson P.K.;
RT   "Plk1 regulates activation of the anaphase promoting complex by
RT   phosphorylating and triggering SCFbetaTrCP-dependent destruction of
RT   the APC inhibitor Emi1.";
RL   Mol. Biol. Cell 15:5623-5634(2004).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF WEE1.
RX   PubMed=15070733; DOI=10.1073/pnas.0307700101;
RA   Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N.,
RA   Hunter T., Osada H.;
RT   "M-phase kinases induce phospho-dependent ubiquitination of somatic
RT   Wee1 by SCFbeta-TrCP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4419-4424(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF FBXO5.
RX   PubMed=15148369; DOI=10.1073/pnas.0402442101;
RA   Moshe Y., Boulaire J., Pagano M., Hershko A.;
RT   "Role of Polo-like kinase in the degradation of early mitotic
RT   inhibitor 1, a regulator of the anaphase promoting
RT   complex/cyclosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:7937-7942(2004).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF CEP55.
RX   PubMed=16198290; DOI=10.1016/j.devcel.2005.09.003;
RA   Fabbro M., Zhou B.-B., Takahashi M., Sarcevic B., Lal P., Graham M.E.,
RA   Gabrielli B.G., Robinson P.J., Nigg E.A., Ono Y., Khanna K.K.;
RT   "Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome
RT   protein, Cep55, is required for its recruitment to midbody and
RT   cytokinesis.";
RL   Dev. Cell 9:477-488(2005).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, AND INTERACTION WITH HSF1.
RX   PubMed=15661742; DOI=10.1074/jbc.M411908200;
RA   Kim S.A., Yoon J.H., Lee S.H., Ahn S.G.;
RT   "Polo-like kinase 1 phosphorylates heat shock transcription factor 1
RT   and mediates its nuclear translocation during heat stress.";
RL   J. Biol. Chem. 280:12653-12657(2005).
RN   [24]
RP   INTERACTION WITH CEP170.
RX   PubMed=15616186; DOI=10.1091/mbc.E04-10-0939;
RA   Guarguaglini G., Duncan P.I., Stierhof Y.D., Holmstroem T.,
RA   Duensing S., Nigg E.A.;
RT   "The forkhead-associated domain protein Cep170 interacts with Polo-
RT   like kinase 1 and serves as a marker for mature centrioles.";
RL   Mol. Biol. Cell 16:1095-1107(2005).
RN   [25]
RP   INTERACTION WITH EVI5.
RX   PubMed=16439210; DOI=10.1016/j.cell.2005.10.038;
RA   Eldridge A.G., Loktev A.V., Hansen D.V., Verschuren E.W.,
RA   Reimann J.D.R., Jackson P.K.;
RT   "The evi5 oncogene regulates cyclin accumulation by stabilizing the
RT   anaphase-promoting complex inhibitor emi1.";
RL   Cell 124:367-380(2006).
RN   [26]
RP   SUBCELLULAR LOCATION, INTERACTION WITH BUB1 AND BUB1B, AND MUTAGENESIS
RP   OF HIS-538 AND LYS-540.
RX   PubMed=16760428; DOI=10.1091/mbc.E06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF KIZ.
RX   PubMed=16980960; DOI=10.1038/ncb1474;
RA   Oshimori N., Ohsugi M., Yamamoto T.;
RT   "The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure
RT   spindle bipolarity.";
RL   Nat. Cell Biol. 8:1095-1101(2006).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF ECT2, AND INTERACTION WITH ECT2.
RX   PubMed=16247472; DOI=10.1038/sj.onc.1209124;
RA   Niiya F., Tatsumoto T., Lee K.S., Miki T.;
RT   "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase
RT   stimulates association of the mitotic kinase Plk1 and accumulation of
RT   GTP-bound RhoA.";
RL   Oncogene 25:827-837(2006).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF CENPU.
RX   PubMed=17081991; DOI=10.1016/j.molcel.2006.10.016;
RA   Kang Y.H., Park J.-E., Yu L.-R., Soung N.-K., Yun S.-M., Bang J.K.,
RA   Seong Y.-S., Yu H., Garfield S., Veenstra T.D., Lee K.S.;
RT   "Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1
RT   interaction is critical for proper chromosome segregation.";
RL   Mol. Cell 24:409-422(2006).
RN   [30]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=16645325; DOI=10.1159/000093003;
RA   Kanaji S., Saito H., Tsujitani S., Matsumoto S., Tatebe S., Kondo A.,
RA   Ozaki M., Ito H., Ikeguchi M.;
RT   "Expression of polo-like kinase 1 (PLK1) protein predicts the survival
RT   of patients with gastric carcinoma.";
RL   Oncology 70:126-133(2006).
RN   [31]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17981789; DOI=10.1158/0008-5472.CAN-07-1887;
RA   Salvatore G., Nappi T.C., Salerno P., Jiang Y., Garbi C., Ugolini C.,
RA   Miccoli P., Basolo F., Castellone M.D., Cirafici A.M., Melillo R.M.,
RA   Fusco A., Bittner M.L., Santoro M.;
RT   "A cell proliferation and chromosomal instability signature in
RT   anaplastic thyroid carcinoma.";
RL   Cancer Res. 67:10148-10158(2007).
RN   [32]
RP   INTERACTION WITH ERCC6L.
RX   PubMed=17218258; DOI=10.1016/j.cell.2006.11.041;
RA   Baumann C., Koerner R., Hofmann K., Nigg E.A.;
RT   "PICH, a centromere-associated SNF2 family ATPase, is regulated by
RT   Plk1 and required for the spindle checkpoint.";
RL   Cell 128:101-114(2007).
RN   [33]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17617734; DOI=10.4161/cc.6.13.4442;
RA   Pouwels J., Kukkonen A.M., Lan W., Daum J.R., Gorbsky G.J.,
RA   Stukenberg T., Kallio M.J.;
RT   "Shugoshin 1 plays a central role in kinetochore assembly and is
RT   required for kinetochore targeting of Plk1.";
RL   Cell Cycle 6:1579-1585(2007).
RN   [34]
RP   INTERACTION WITH TTDN1.
RX   PubMed=17310276; DOI=10.1007/s00018-007-6501-8;
RA   Zhang Y., Tian Y., Chen Q., Chen D., Zhai Z., Shu H.-B.;
RT   "TTDN1 is a Plk1-interacting protein involved in maintenance of cell
RT   cycle integrity.";
RL   Cell. Mol. Life Sci. 64:632-640(2007).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF BUB1B.
RX   PubMed=17376779; DOI=10.1074/jbc.M611053200;
RA   Matsumura S., Toyoshima F., Nishida E.;
RT   "Polo-like kinase 1 facilitates chromosome alignment during
RT   prometaphase through BubR1.";
RL   J. Biol. Chem. 282:15217-15227(2007).
RN   [36]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17943598; DOI=10.1080/10428190701615918;
RA   Liu L., Zhang M., Zou P.;
RT   "Expression of PLK1 and survivin in diffuse large B-cell lymphoma.";
RL   Leuk. Lymphoma 48:2179-2183(2007).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF PRC1, AND DOMAIN POLO BOX.
RX   PubMed=17351640; DOI=10.1038/ncb1557;
RA   Neef R., Gruneberg U., Kopajtich R., Li X., Nigg E.A., Sillje H.,
RA   Barr F.A.;
RT   "Choice of Plk1 docking partners during mitosis and cytokinesis is
RT   controlled by the activation state of Cdk1.";
RL   Nat. Cell Biol. 9:436-444(2007).
RN   [38]
RP   INTERACTION WITH CYLD, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17495026; DOI=10.1073/pnas.0703268104;
RA   Stegmeier F., Sowa M.E., Nalepa G., Gygi S.P., Harper J.W.,
RA   Elledge S.J.;
RT   "The tumor suppressor CYLD regulates entry into mitosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8869-8874(2007).
RN   [39]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, INTERACTION WITH HSF1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18794143; DOI=10.1158/0008-5472.CAN-08-0129;
RA   Lee Y.J., Kim E.H., Lee J.S., Jeoung D., Bae S., Kwon S.H., Lee Y.S.;
RT   "HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is
RT   essential for mitotic progression.";
RL   Cancer Res. 68:7550-7560(2008).
RN   [40]
RP   UBIQUITINATION BY THE APC/C COMPLEX, INTERACTION WITH FZR1, AND
RP   MUTAGENESIS OF ARG-337 AND LEU-340.
RX   PubMed=18662541; DOI=10.1016/j.cell.2008.05.043;
RA   Bassermann F., Frescas D., Guardavaccaro D., Busino L.,
RA   Peschiaroli A., Pagano M.;
RT   "The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response
RT   checkpoint.";
RL   Cell 134:256-267(2008).
RN   [41]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled
RT   by BRUCE.";
RL   Cell 132:832-845(2008).
RN   [42]
RP   FUNCTION IN PHOSPHORYLATION OF TP73.
RX   PubMed=18418051; DOI=10.4161/cc.7.9.5777;
RA   Soond S.M., Barry S.P., Melino G., Knight R.A., Latchman D.S.,
RA   Stephanou A.;
RT   "p73-mediated transcriptional activity is negatively regulated by
RT   polo-like kinase 1.";
RL   Cell Cycle 7:1214-1223(2008).
RN   [43]
RP   FUNCTION, AND INTERACTION WITH PHOSPHORYLATED BORA.
RX   PubMed=18521620; DOI=10.1007/s00412-008-0165-5;
RA   Chan E.H., Santamaria A., Sillje H.H., Nigg E.A.;
RT   "Plk1 regulates mitotic Aurora A function through betaTrCP-dependent
RT   degradation of hBora.";
RL   Chromosoma 117:457-469(2008).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF SGO1, AND INTERACTION WITH SGO1.
RX   PubMed=18331714; DOI=10.1016/j.devcel.2007.12.007;
RA   Wang X., Yang Y., Duan Q., Jiang N., Huang Y., Darzynkiewicz Z.,
RA   Dai W.;
RT   "sSgo1, a major splice variant of Sgo1, functions in centriole
RT   cohesion where it is regulated by Plk1.";
RL   Dev. Cell 14:331-341(2008).
RN   [45]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A, PHOSPHORYLATION AT THR-210,
RP   DEPHOSPHORYLATION BY PPP1C, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   HIS-538 AND LYS-540.
RX   PubMed=18477460; DOI=10.1016/j.devcel.2008.02.013;
RA   Yamashiro S., Yamakita Y., Totsukawa G., Goto H., Kaibuchi K., Ito M.,
RA   Hartshorne D.J., Matsumura F.;
RT   "Myosin phosphatase-targeting subunit 1 regulates mitosis by
RT   antagonizing polo-like kinase 1.";
RL   Dev. Cell 14:787-797(2008).
RN   [46]
RP   FUNCTION IN PHOSPHORYLATION OF TP73, AND MUTAGENESIS OF LYS-82.
RX   PubMed=18174154; DOI=10.1074/jbc.M710608200;
RA   Koida N., Ozaki T., Yamamoto H., Ono S., Koda T., Ando K., Okoshi R.,
RA   Kamijo T., Omura K., Nakagawara A.;
RT   "Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis
RT   through physical interaction and phosphorylation.";
RL   J. Biol. Chem. 283:8555-8563(2008).
RN   [47]
RP   INTERACTION WITH FAM29A.
RX   PubMed=19029337; DOI=10.1083/jcb.200807046;
RA   Zhu H., Coppinger J.A., Jang C.-Y., Yates J.R. III, Fang G.;
RT   "FAM29A promotes microtubule amplification via recruitment of the
RT   NEDD1-gamma-tubulin complex to the mitotic spindle.";
RL   J. Cell Biol. 183:835-848(2008).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-6; SER-103; THR-210;
RP   THR-214; SER-375; SER-450 AND THR-498, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [49]
RP   FUNCTION IN PHOSPHORYLATION OF FOXM1, AND MUTAGENESIS OF LYS-82 AND
RP   THR-210.
RX   PubMed=19160488; DOI=10.1038/ncb1767;
RA   Fu Z., Malureanu L., Huang J., Wang W., Li H., van Deursen J.M.,
RA   Tindall D.J., Chen J.;
RT   "Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional
RT   programme required for mitotic progression.";
RL   Nat. Cell Biol. 10:1076-1082(2008).
RN   [50]
RP   FUNCTION, ENZYME REGULATION, PHOSPHORYLATION AT THR-210 BY AURKA,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-82; SER-137; ASP-176 AND
RP   THR-210.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R.,
RA   Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [52]
RP   INTERACTION WITH SLX4.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [53]
RP   FUNCTION IN PHOSPHORYLATION OF TOPORS, AND INTERACTION WITH TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [54]
RP   FUNCTION AS NEDD1 KINASE.
RX   PubMed=19509060; DOI=10.1242/jcs.042747;
RA   Zhang X., Chen Q., Feng J., Hou J., Yang F., Liu J., Jiang Q.,
RA   Zhang C.;
RT   "Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for
RT   targeting of the gammaTuRC to the centrosome.";
RL   J. Cell Sci. 122:2240-2251(2009).
RN   [55]
RP   FUNCTION, INTERACTION WITH KIF2A, AND SUBCELLULAR LOCATION.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210 AND THR-214, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [57]
RP   FUNCTION IN PHOSPHORYLATION OF RACGAP1, INTERACTION WITH PRC1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19468300; DOI=10.1371/journal.pbio.1000110;
RA   Wolfe B.A., Takaki T., Petronczki M., Glotzer M.;
RT   "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF
RT   complex to initiate cleavage furrow formation.";
RL   PLoS Biol. 7:E1000110-E1000110(2009).
RN   [58]
RP   FUNCTION IN PHOSPHORYLATION OF RACGAP1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF CYS-67; LEU-130; HIS-538 AND LYS-540.
RX   PubMed=19468302; DOI=10.1371/journal.pbio.1000111;
RA   Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M.,
RA   Lowery D.M., Clauser K.R., Zhang C., Shokat K.M., Carr S.A.,
RA   Yaffe M.B., Jallepalli P.V.;
RT   "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the
RT   spindle midzone regulate the onset of division in human cells.";
RL   PLoS Biol. 7:E1000111-E1000111(2009).
RN   [59]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=20671765; DOI=10.1038/nrd3184;
RA   Strebhardt K.;
RT   "Multifaceted polo-like kinases: drug targets and antitargets for
RT   cancer therapy.";
RL   Nat. Rev. Drug Discov. 9:643-660(2010).
RN   [60]
RP   FUNCTION IN PHOSPHORYLATION OF DCTN1, AND INTERACTION WITH DCTN1.
RX   PubMed=20679239; DOI=10.1073/pnas.1006615107;
RA   Li H., Liu X.S., Yang X., Song B., Wang Y., Liu X.;
RT   "Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear
RT   envelope breakdown during prophase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14633-14638(2010).
RN   [61]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [63]
RP   IDENTIFICATION IN A COMPLEX WITH KNSTRN; SPAG5; DYNLL1 AND SGO2.
RX   PubMed=21402792; DOI=10.1083/jcb.201008023;
RA   Dunsch A.K., Linnane E., Barr F.A., Gruneberg U.;
RT   "The astrin-kinastrin/SKAP complex localizes to microtubule plus ends
RT   and facilitates chromosome alignment.";
RL   J. Cell Biol. 192:959-968(2011).
RN   [64]
RP   INTERACTION WITH FRY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-194.
RX   PubMed=22753416; DOI=10.1074/jbc.M112.378968;
RA   Ikeda M., Chiba S., Ohashi K., Mizuno K.;
RT   "Furry protein promotes Aurora A-mediated polo-like kinase 1
RT   activation.";
RL   J. Biol. Chem. 287:27670-27681(2012).
RN   [65]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [66]
RP   INTERACTION WITH FOPNL, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-82; TRP-414; VAL-415 AND LEU-427.
RX   PubMed=24018379; DOI=10.1038/cr.2013.127;
RA   Shen M., Cai Y., Yang Y., Yan X., Liu X., Zhou T.;
RT   "Centrosomal protein FOR20 is essential for S-phase progression by
RT   recruiting Plk1 to centrosomes.";
RL   Cell Res. 23:1284-1295(2013).
RN   [67]
RP   INTERACTION WITH DCTN6, AND SUBCELLULAR LOCATION.
RX   PubMed=23455152; DOI=10.1038/emboj.2013.30;
RA   Yeh T.Y., Kowalska A.K., Scipioni B.R., Cheong F.K., Zheng M.,
RA   Derewenda U., Derewenda Z.S., Schroer T.A.;
RT   "Dynactin helps target Polo-like kinase 1 to kinetochores via its
RT   left-handed beta-helical p27 subunit.";
RL   EMBO J. 32:1023-1035(2013).
RN   [68]
RP   FUNCTION IN PHOSPHORYLATION OF MISP.
RX   PubMed=23509069; DOI=10.1083/jcb.201207050;
RA   Zhu M., Settele F., Kotak S., Sanchez-Pulido L., Ehret L.,
RA   Ponting C.P., Goenczy P., Hoffmann I.;
RT   "MISP is a novel Plk1 substrate required for proper spindle
RT   orientation and mitotic progression.";
RL   J. Cell Biol. 200:773-787(2013).
RN   [69]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [70]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-9 AND LYS-492,
RP   AND MUTAGENESIS OF LYS-492.
RX   PubMed=23455478; DOI=10.1038/ncb2695;
RA   Beck J., Maerki S., Posch M., Metzger T., Persaud A., Scheel H.,
RA   Hofmann K., Rotin D., Pedrioli P., Swedlow J.R., Peter M., Sumara I.;
RT   "Ubiquitylation-dependent localization of PLK1 in mitosis.";
RL   Nat. Cell Biol. 15:430-439(2013).
RN   [71]
RP   FUNCTION, AND INTERACTION WITH CEP68.
RX   PubMed=25503564; DOI=10.1038/ncb3076;
RA   Pagan J.K., Marzio A., Jones M.J., Saraf A., Jallepalli P.V.,
RA   Florens L., Washburn M.P., Pagano M.;
RT   "Degradation of Cep68 and PCNT cleavage mediate Cep215 removal from
RT   the PCM to allow centriole separation, disengagement and licensing.";
RL   Nat. Cell Biol. 17:31-43(2015).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, DOMAIN POLO
RP   BOX, INTERACTION WITH CDC25C, AND MUTAGENESIS OF HIS-538 AND LYS-540.
RX   PubMed=14532005; DOI=10.1016/S0092-8674(03)00725-6;
RA   Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K.,
RA   Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B.;
RT   "The molecular basis for phosphodependent substrate targeting and
RT   regulation of Plks by the Polo-box domain.";
RL   Cell 115:83-95(2003).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 367-603 IN COMPLEX WITH
RP   PHOSPHORYLATED PEPTIDE.
RX   PubMed=14592974; DOI=10.1093/emboj/cdg558;
RA   Cheng K.Y., Lowe E.D., Sinclair J., Nigg E.A., Johnson L.N.;
RT   "The crystal structure of the human polo-like kinase-1 polo box domain
RT   and its phospho-peptide complex.";
RL   EMBO J. 22:5757-5768(2003).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 13-345 OF MUTANT VAL-210 IN
RP   COMPLEXES WITH ATP ANALOGS, AND MUTAGENESIS OF THR-210.
RX   PubMed=17461553; DOI=10.1021/bi602474j;
RA   Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L.,
RA   Johnson T.L., Lewis C., Loh C., Nonomiya J., Sheils A.L.,
RA   Verdries K.A., Wynn T.A., Kuhn C., Ding Y.H.;
RT   "Structure of the catalytic domain of human polo-like kinase 1.";
RL   Biochemistry 46:5960-5971(2007).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 37-330 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR BI 2536.
RX   PubMed=18005335; DOI=10.1111/j.1747-0285.2007.00594.x;
RA   Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., Kuhn C.,
RA   Ding Y.H.;
RT   "Selectivity-determining residues in Plk1.";
RL   Chem. Biol. Drug Des. 70:540-546(2007).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 365-603 IN COMPLEX WITH
RP   CDC25C, SUBCELLULAR LOCATION, INTERACTION WITH CDC25C, ENZYME
RP   REGULATION, AND MUTAGENESIS OF TRP-414.
RX   PubMed=17307877; DOI=10.1073/pnas.0609131104;
RA   Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E.,
RA   Montoya G.;
RT   "Molecular and structural basis of polo-like kinase 1 substrate
RT   recognition: Implications in centrosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3107-3112(2007).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-345 IN COMPLEX WITH A
RP   DARPIN.
RX   PubMed=18391401; DOI=10.1107/S0907444907068217;
RA   Bandeiras T.M., Hillig R.C., Matias P.M., Eberspaecher U.,
RA   Fanghanel J., Thomaz M., Miranda S., Crusius K., Putter V.,
RA   Amstutz P., Gulotti-Georgieva M., Binz H.K., Holz C., Schmitz A.A.,
RA   Lang C., Donner P., Egner U., Carrondo M.A., Muller-Tiemann B.;
RT   "Structure of wild-type Plk-1 kinase domain in complex with a
RT   selective DARPin.";
RL   Acta Crystallogr. D 64:339-353(2008).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 371-603 IN COMPLEX WITH
RP   PHOSPHOPEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   PHOSPHORYLATED CENPU.
RX   PubMed=19597481; DOI=10.1038/nsmb.1628;
RA   Yun S.M., Moulaei T., Lim D., Bang J.K., Park J.E., Shenoy S.R.,
RA   Liu F., Kang Y.H., Liao C., Soung N.K., Lee S., Yoon D.Y., Lim Y.,
RA   Lee D.H., Otaka A., Appella E., McMahon J.B., Nicklaus M.C.,
RA   Burke T.R. Jr., Yaffe M.B., Wlodawer A., Lee K.S.;
RT   "Structural and functional analyses of minimal phosphopeptides
RT   targeting the polo-box domain of polo-like kinase 1.";
RL   Nat. Struct. Mol. Biol. 16:876-882(2009).
RN   [79]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-12; PHE-261; VAL-332; HIS-463 AND
RP   HIS-518.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that performs several
CC       important functions throughout M phase of the cell cycle,
CC       including the regulation of centrosome maturation and spindle
CC       assembly, the removal of cohesins from chromosome arms, the
CC       inactivation of anaphase-promoting complex/cyclosome (APC/C)
CC       inhibitors, and the regulation of mitotic exit and cytokinesis.
CC       Polo-like kinase proteins acts by binding and phosphorylating
CC       proteins are that already phosphorylated on a specific motif
CC       recognized by the POLO box domains. Phosphorylates BORA,
CC       BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1,
CC       FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1,
CC       KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14,
CC       TOPORS, p73/TP73, TPT1 and WEE1. Plays a key role in centrosome
CC       functions and the assembly of bipolar spindles by phosphorylating
CC       KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent
CC       targeting of the gamma-tubulin ring complex (gTuRC) to the
CC       centrosome, an important step for spindle formation.
CC       Phosphorylation of NINL component of the centrosome leads to NINL
CC       dissociation from other centrosomal proteins. Involved in mitosis
CC       exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2,
CC       CENPU, PRC1 and RACGAP1. Recruited at the central spindle by
CC       phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own
CC       docking sites on PRC1 and KIF20A/MKLP2 by mediating
CC       phosphorylation of sites subsequently recognized by the POLO box
CC       domains. Phosphorylates RACGAP1, thereby creating a docking site
CC       for the Rho GTP exchange factor ECT2 that is essential for the
CC       cleavage furrow formation. Promotes the central spindle
CC       recruitment of ECT2. Plays a central role in G2/M transition of
CC       mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU,
CC       PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit
CC       that promotes the activation of CDK1 by phosphorylating the
CC       positive regulator CDC25C and inhibiting the negative regulators
CC       WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of
CC       cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates
CC       FOXM1, a key mitotic transcription regulator, leading to enhance
CC       FOXM1 transcriptional activity. Involved in kinetochore functions
CC       and sister chromatid cohesion by phosphorylating BUB1B/BUBR1,
CC       FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached
CC       kinetochores suggesting a role of PLK1 in kinetochore attachment
CC       or in spindle assembly checkpoint (SAC) regulation. Required for
CC       kinetochore localization of BUB1B. Regulates the dissociation of
CC       cohesin from chromosomes by phosphorylating cohesin subunits such
CC       as STAG2/SA2. Phosphorylates SGO1: required for spindle pole
CC       localization of isoform 3 of SGO1 and plays a role in regulating
CC       its centriole cohesion function. Mediates phosphorylation of
CC       FBXO5/EMI1, a negative regulator of the APC/C complex during
CC       prophase, leading to FBXO5/EMI1 ubiquitination and degradation by
CC       the proteasome. Acts as a negative regulator of p53 family
CC       members: phosphorylates TOPORS, leading to inhibit the sumoylation
CC       of p53/TP53 and simultaneously enhance the ubiquitination and
CC       subsequent degradation of p53/TP53. Phosphorylates the
CC       transactivation domain of the transcription factor p73/TP73,
CC       leading to inhibit p73/TP73-mediated transcriptional activation
CC       and pro-apoptotic functions. Phosphorylates BORA, and thereby
CC       promotes the degradation of BORA. Contributes to the regulation of
CC       AURKA function. Also required for recovery after DNA damage
CC       checkpoint and entry into mitosis. Phosphorylates MISP, leading to
CC       stabilization of cortical and astral microtubule attachments
CC       required for proper spindle positioning (PubMed:8991084,
CC       PubMed:11202906, PubMed:12207013, PubMed:12447691,
CC       PubMed:12524548, PubMed:12738781, PubMed:12852856,
CC       PubMed:12939256, PubMed:14532005, PubMed:14734534,
CC       PubMed:15070733, PubMed:15148369, PubMed:15469984,
CC       PubMed:16198290, PubMed:16247472, PubMed:16980960,
CC       PubMed:17081991, PubMed:17351640, PubMed:17376779,
CC       PubMed:17617734, PubMed:18174154, PubMed:18331714,
CC       PubMed:18418051, PubMed:18477460, PubMed:18521620,
CC       PubMed:18615013, PubMed:19160488, PubMed:19351716,
CC       PubMed:19468300, PubMed:19468302, PubMed:19473992,
CC       PubMed:19509060, PubMed:19597481, PubMed:23455478,
CC       PubMed:23509069). Together with MEIKIN, acts as a regulator of
CC       kinetochore function during meiosis I: required both for mono-
CC       orientation of kinetochores on sister chromosomes and protection
CC       of centromeric cohesin from separase-mediated cleavage (By
CC       similarity). Phosphorylates CEP68 and is required for its
CC       degradation (PubMed:25503564). Regulates nuclear envelope
CC       breakdown during prophase by phosphorylating DCTN1 resulting in
CC       its localization in the nuclear envelope (PubMed:20679239).
CC       Phosphorylates the heat shock transcription factor HSF1, promoting
CC       HSF1 nuclear translocation upon heat shock (PubMed:15661742).
CC       Phosphorylates HSF1 also in the early mitotic period; this
CC       phosphorylation regulates HSF1 localization to the spindle pole,
CC       the recruitment of the SCF(BTRC) ubiquitin ligase complex
CC       induicing HSF1 degradation, and hence mitotic progression
CC       (PubMed:18794143). {ECO:0000250|UniProtKB:Q5F2C3,
CC       ECO:0000269|PubMed:11202906, ECO:0000269|PubMed:12207013,
CC       ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:12524548,
CC       ECO:0000269|PubMed:12738781, ECO:0000269|PubMed:12852856,
CC       ECO:0000269|PubMed:12939256, ECO:0000269|PubMed:14532005,
CC       ECO:0000269|PubMed:14734534, ECO:0000269|PubMed:15070733,
CC       ECO:0000269|PubMed:15148369, ECO:0000269|PubMed:15469984,
CC       ECO:0000269|PubMed:15661742, ECO:0000269|PubMed:16198290,
CC       ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:16980960,
CC       ECO:0000269|PubMed:17081991, ECO:0000269|PubMed:17351640,
CC       ECO:0000269|PubMed:17376779, ECO:0000269|PubMed:17617734,
CC       ECO:0000269|PubMed:18174154, ECO:0000269|PubMed:18331714,
CC       ECO:0000269|PubMed:18418051, ECO:0000269|PubMed:18477460,
CC       ECO:0000269|PubMed:18521620, ECO:0000269|PubMed:18615013,
CC       ECO:0000269|PubMed:18794143, ECO:0000269|PubMed:19160488,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19468300,
CC       ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19509060, ECO:0000269|PubMed:19597481,
CC       ECO:0000269|PubMed:20679239, ECO:0000269|PubMed:23455478,
CC       ECO:0000269|PubMed:23509069, ECO:0000269|PubMed:25503564,
CC       ECO:0000269|PubMed:8991084}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by phosphorylation of Thr-210 by
CC       AURKA; phosphorylation by AURKA is enhanced by BORA. Once
CC       activated, activity is stimulated by binding target proteins.
CC       Binding of target proteins has no effect on the non-activated
CC       kinase. Several inhibitors targeting PLKs are currently in
CC       development and are under investigation in a growing number of
CC       clinical trials, such as BI 2536, an ATP-competitive PLK1
CC       inhibitor or BI 6727, a dihydropteridinone that specifically
CC       inhibits the catalytic activity of PLK1.
CC       {ECO:0000269|PubMed:17307877, ECO:0000269|PubMed:18615013}.
CC   -!- SUBUNIT: Interacts with CEP170 and EVI5. Interacts and
CC       phosphorylates ERCC6L. Interacts with FAM29A. Interacts with
CC       SLX4/BTBD12 and TTDN1. Interacts with BUB1B. Interacts (via POLO-
CC       box domain) with the phosphorylated form of BUB1, CENPU and
CC       CDC25C. Interacts with isoform 3 of SGO1. Interacts with BORA,
CC       KIF2A and AURKA. Interacts with TOPORS and CYLD. Interacts with
CC       ECT2; the interaction is stimulated upon phosphorylation of ECT2
CC       on 'Thr-444'. Interacts with PRC1. Interacts with KIF20A/MKLP2
CC       (when phosphorylated), leading to the recruitment at the central
CC       spindle. Interacts (via POLO box domains) with PPP1R12A/MYPT1
CC       (when previously phosphorylated by CDK1). Part of an astrin
CC       (SPAG5)-kinastrin (SKAP) complex containing KNSTRN, SPAG5, PLK1,
CC       DYNLL1 and SGO2. Interacts with BIRC6/bruce. Interacts with CDK1-
CC       phosphorylated FRY; this interaction occurs in mitotic cells, but
CC       not in interphase cells. FRY interaction facilitates AURKA-
CC       mediated PLK1 phosphorylation. Interacts with CDK1-phosphorylated
CC       DCTN6 during mitotic prometaphase; the interaction facilitates
CC       recruitment to kinetochores. Interacts with CEP68; the interaction
CC       phosphorylates CEP68 (PubMed:25503564). Interacts (via POLO-box
CC       domain) with DCTN1 (PubMed:20679239). Interacts with FOPNL in
CC       later G1, S, G2 and M phases of the cell cycle; this interaction
CC       recruits PLK1 to centrosomes, a step required for S phase
CC       progression (PubMed:24018379). Interacts with HSF1; this
CC       interaction increases upon heat shock but does not modulate
CC       neither HSF1 homotrimerization nor DNA-binding activities
CC       (PubMed:15661742, PubMed:18794143). {ECO:0000269|PubMed:12939256,
CC       ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:14592974,
CC       ECO:0000269|PubMed:15616186, ECO:0000269|PubMed:15661742,
CC       ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:16439210,
CC       ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:17218258,
CC       ECO:0000269|PubMed:17307877, ECO:0000269|PubMed:17310276,
CC       ECO:0000269|PubMed:17495026, ECO:0000269|PubMed:18005335,
CC       ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18331714,
CC       ECO:0000269|PubMed:18391401, ECO:0000269|PubMed:18521620,
CC       ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:18794143,
CC       ECO:0000269|PubMed:19029337, ECO:0000269|PubMed:19351716,
CC       ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19596235, ECO:0000269|PubMed:19597481,
CC       ECO:0000269|PubMed:20679239, ECO:0000269|PubMed:21402792,
CC       ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23455152,
CC       ECO:0000269|PubMed:24018379, ECO:0000269|PubMed:25503564}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=4; IntAct=EBI-476768, EBI-6927873;
CC       Q9NR09:BIRC6; NbExp=4; IntAct=EBI-476768, EBI-1765160;
CC       O96017:CHEK2; NbExp=6; IntAct=EBI-476768, EBI-1180783;
CC       Q60838:Dvl2 (xeno); NbExp=12; IntAct=EBI-476768, EBI-641940;
CC       P23588:EIF4B; NbExp=3; IntAct=EBI-476768, EBI-970310;
CC       Q2NKX8:ERCC6L; NbExp=3; IntAct=EBI-476768, EBI-1042535;
CC       O60447:EVI5; NbExp=3; IntAct=EBI-476768, EBI-852291;
CC       Q13158:FADD; NbExp=9; IntAct=EBI-476768, EBI-494804;
CC       Q9NYZ3:GTSE1; NbExp=6; IntAct=EBI-476768, EBI-2511327;
CC       P08107:HSPA1B; NbExp=5; IntAct=EBI-476768, EBI-629985;
CC       P49736:MCM2; NbExp=2; IntAct=EBI-476768, EBI-374819;
CC       P33993:MCM7; NbExp=4; IntAct=EBI-476768, EBI-355924;
CC       Q00987:MDM2; NbExp=7; IntAct=EBI-476768, EBI-389668;
CC       P23804:Mdm2 (xeno); NbExp=2; IntAct=EBI-476768, EBI-641788;
CC       Q8TD19:NEK9; NbExp=5; IntAct=EBI-476768, EBI-1044009;
CC       O75665:OFD1; NbExp=4; IntAct=EBI-476768, EBI-716327;
CC       Q8IXK0:PHC2; NbExp=2; IntAct=EBI-476768, EBI-713786;
CC       Q8IY92:SLX4; NbExp=7; IntAct=EBI-476768, EBI-2370740;
CC       Q92844:TANK; NbExp=3; IntAct=EBI-476768, EBI-356349;
CC       P04637:TP53; NbExp=6; IntAct=EBI-476768, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere,
CC       kinetochore. Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:24018379}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000269|PubMed:18794143}. Midbody.
CC       Note=localization at the centrosome starts at the G1/S transition
CC       (PubMed:24018379). During early stages of mitosis, the
CC       phosphorylated form is detected on centrosomes and kinetochores.
CC       Localizes to the outer kinetochore. Presence of SGO1 and
CC       interaction with the phosphorylated form of BUB1 is required for
CC       the kinetochore localization. Localizes onto the central spindle
CC       by phosphorylating and docking at midzone proteins KIF20A/MKLP2
CC       and PRC1. Colocalizes with FRY to separating centrosomes and
CC       spindle poles from prophase to metaphase in mitosis, but not in
CC       other stages of the cell cycle. Localization to the centrosome is
CC       required for S phase progression (PubMed:24018379). Colocalizes
CC       with HSF1 at the spindle poles during prometaphase
CC       (PubMed:18794143). {ECO:0000269|PubMed:18794143,
CC       ECO:0000269|PubMed:24018379}.
CC   -!- TISSUE SPECIFICITY: Placenta and colon.
CC   -!- DEVELOPMENTAL STAGE: Accumulates to a maximum during the G2 and M
CC       phases, declines to a nearly undetectable level following mitosis
CC       and throughout G1 phase, and then begins to accumulate again
CC       during S phase.
CC   -!- INDUCTION: By growth-stimulating agents.
CC   -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module
CC       that recognize and bind serine-[phosphothreonine/phosphoserine]-
CC       (proline/X) motifs. PLK1 recognizes and binds docking proteins
CC       that are already phosphorylated on these motifs, and then
CC       phosphorylates them. PLK1 can also create its own docking sites by
CC       mediating phosphorylation of serine-
CC       [phosphothreonine/phosphoserine]-(proline/X) motifs subsequently
CC       recognized by the POLO box domains. {ECO:0000269|PubMed:12939256,
CC       ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:14734534,
CC       ECO:0000269|PubMed:17351640}.
CC   -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-210.
CC       Phosphorylation at Thr-210 is first detected on centrosomes in the
CC       G2 phase of the cell cycle, peaks in prometaphase and gradually
CC       disappears from centrosomes during anaphase. Dephosphorylation at
CC       Thr-210 at centrosomes is probably mediated by protein phosphatase
CC       1C (PP1C), via interaction with PPP1R12A/MYPT1.
CC       Autophosphorylation and phosphorylation of Ser-137 may not be
CC       significant for the activation of PLK1 during mitosis, but may
CC       enhance catalytic activity during recovery after DNA damage
CC       checkpoint. Phosphorylated in vitro by STK10.
CC       {ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:12442251,
CC       ECO:0000269|PubMed:12639966, ECO:0000269|PubMed:18477460,
CC       ECO:0000269|PubMed:18615013}.
CC   -!- PTM: Ubiquitinated by the anaphase promoting complex/cyclosome
CC       (APC/C) in anaphase and following DNA damage, leading to its
CC       degradation by the proteasome. Ubiquitination is mediated via its
CC       interaction with FZR1/CDH1. Ubiquitination and subsequent
CC       degradation prevents entry into mitosis and is essential to
CC       maintain an efficient G2 DNA damage checkpoint. Monoubiquitination
CC       at Lys-492 by the BCR(KLHL22) ubiquitin ligase complex does not
CC       lead to degradation: it promotes PLK1 dissociation from
CC       phosphoreceptor proteins and subsequent removal from kinetochores,
CC       allowing silencing of the spindle assembly checkpoint (SAC) and
CC       chromosome segregation. {ECO:0000269|PubMed:18662541,
CC       ECO:0000269|PubMed:23455478}.
CC   -!- DISEASE: Note=Defects in PLK1 are associated with some cancers,
CC       such as gastric, thyroid or B-cell lymphomas. Expression is cancer
CC       increased in tumor tissues with a poor prognosis, suggesting a
CC       role in malignant transformations and carcinogenesis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PLK1ID41747ch16p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U01038; AAA56634.1; -; mRNA.
DR   EMBL; L19559; AAA36659.1; -; mRNA.
DR   EMBL; X73458; CAA51837.1; -; mRNA.
DR   EMBL; X75932; CAA53536.1; -; mRNA.
DR   EMBL; BC002369; AAH02369.1; -; mRNA.
DR   EMBL; BC003002; AAH03002.1; -; mRNA.
DR   EMBL; BC014846; AAH14846.1; -; mRNA.
DR   EMBL; X90725; CAA62260.1; -; Genomic_DNA.
DR   EMBL; U78073; AAB36946.1; -; Genomic_DNA.
DR   CCDS; CCDS10616.1; -.
DR   PIR; S34130; S34130.
DR   RefSeq; NP_005021.2; NM_005030.5.
DR   UniGene; Hs.592049; -.
DR   PDB; 1Q4K; X-ray; 2.30 A; A/B/C=345-603.
DR   PDB; 1Q4O; X-ray; 2.20 A; A/B=367-603.
DR   PDB; 1UMW; X-ray; 1.90 A; A/B=367-603.
DR   PDB; 2OGQ; X-ray; 1.95 A; A=365-603.
DR   PDB; 2OJX; X-ray; 2.85 A; A=365-603.
DR   PDB; 2OU7; X-ray; 2.40 A; A=13-345.
DR   PDB; 2OWB; X-ray; 2.10 A; A=13-345.
DR   PDB; 2RKU; X-ray; 1.95 A; A=37-330.
DR   PDB; 2V5Q; X-ray; 2.30 A; A/B=33-345.
DR   PDB; 2YAC; X-ray; 2.20 A; A=36-345.
DR   PDB; 3BZI; X-ray; 2.10 A; A=365-603.
DR   PDB; 3C5L; X-ray; 2.33 A; A=373-593.
DR   PDB; 3FC2; X-ray; 2.45 A; A=13-345.
DR   PDB; 3FVH; X-ray; 1.58 A; A=371-603.
DR   PDB; 3HIH; X-ray; 1.70 A; A/B=371-593.
DR   PDB; 3HIK; X-ray; 1.77 A; A=367-603.
DR   PDB; 3KB7; X-ray; 2.50 A; A=36-345.
DR   PDB; 3P2W; X-ray; 1.66 A; A=371-594.
DR   PDB; 3P2Z; X-ray; 1.79 A; A=371-594.
DR   PDB; 3P34; X-ray; 1.40 A; A=371-594.
DR   PDB; 3P35; X-ray; 2.09 A; A/B/C=371-594.
DR   PDB; 3P36; X-ray; 1.59 A; A=371-594.
DR   PDB; 3P37; X-ray; 2.38 A; A/B/C=371-594.
DR   PDB; 3Q1I; X-ray; 1.40 A; A=371-594.
DR   PDB; 3RQ7; X-ray; 1.55 A; A=371-603.
DR   PDB; 3THB; X-ray; 2.50 A; A=13-345.
DR   PDB; 4A4L; X-ray; 2.35 A; A=36-345.
DR   PDB; 4A4O; X-ray; 2.70 A; A=36-345.
DR   PDB; 4DFW; X-ray; 1.55 A; A=367-603.
DR   PDB; 4E67; X-ray; 2.10 A; A=371-594.
DR   PDB; 4E9C; X-ray; 1.70 A; A=371-594.
DR   PDB; 4E9D; X-ray; 2.75 A; A=371-594.
DR   PDB; 4H5X; X-ray; 1.95 A; A/B=367-603.
DR   PDB; 4H71; X-ray; 1.93 A; A/B=367-603.
DR   PDB; 4HAB; X-ray; 2.65 A; A/B/C=371-593.
DR   PDB; 4HCO; X-ray; 2.75 A; A/B=367-603.
DR   PDB; 4HY2; X-ray; 2.00 A; A=371-595.
DR   PDB; 4J52; X-ray; 2.30 A; A=38-330.
DR   PDB; 4J53; X-ray; 2.50 A; A=38-330.
DR   PDB; 4LKL; X-ray; 1.58 A; A=372-593.
DR   PDB; 4LKM; X-ray; 2.00 A; A/C=371-601.
DR   PDB; 4O56; X-ray; 1.80 A; A=367-603.
DR   PDB; 4O6W; X-ray; 1.45 A; A=371-603.
DR   PDB; 4O9W; X-ray; 1.69 A; A=373-594.
DR   PDB; 4RCP; X-ray; 1.60 A; A=372-599.
DR   PDB; 4WHH; X-ray; 1.90 A; A=371-603.
DR   PDB; 4WHK; X-ray; 1.80 A; A=371-603.
DR   PDB; 4WHL; X-ray; 2.71 A; A=371-603.
DR   PDB; 4X9R; X-ray; 1.40 A; A=371-603.
DR   PDB; 4X9V; X-ray; 1.43 A; A=371-603.
DR   PDB; 4X9W; X-ray; 1.80 A; A=371-603.
DR   PDB; 5J19; X-ray; 2.00 A; A/B=367-594.
DR   PDB; 5TA6; X-ray; 2.50 A; A=13-345.
DR   PDB; 5TA8; X-ray; 2.60 A; A=13-345.
DR   PDBsum; 1Q4K; -.
DR   PDBsum; 1Q4O; -.
DR   PDBsum; 1UMW; -.
DR   PDBsum; 2OGQ; -.
DR   PDBsum; 2OJX; -.
DR   PDBsum; 2OU7; -.
DR   PDBsum; 2OWB; -.
DR   PDBsum; 2RKU; -.
DR   PDBsum; 2V5Q; -.
DR   PDBsum; 2YAC; -.
DR   PDBsum; 3BZI; -.
DR   PDBsum; 3C5L; -.
DR   PDBsum; 3FC2; -.
DR   PDBsum; 3FVH; -.
DR   PDBsum; 3HIH; -.
DR   PDBsum; 3HIK; -.
DR   PDBsum; 3KB7; -.
DR   PDBsum; 3P2W; -.
DR   PDBsum; 3P2Z; -.
DR   PDBsum; 3P34; -.
DR   PDBsum; 3P35; -.
DR   PDBsum; 3P36; -.
DR   PDBsum; 3P37; -.
DR   PDBsum; 3Q1I; -.
DR   PDBsum; 3RQ7; -.
DR   PDBsum; 3THB; -.
DR   PDBsum; 4A4L; -.
DR   PDBsum; 4A4O; -.
DR   PDBsum; 4DFW; -.
DR   PDBsum; 4E67; -.
DR   PDBsum; 4E9C; -.
DR   PDBsum; 4E9D; -.
DR   PDBsum; 4H5X; -.
DR   PDBsum; 4H71; -.
DR   PDBsum; 4HAB; -.
DR   PDBsum; 4HCO; -.
DR   PDBsum; 4HY2; -.
DR   PDBsum; 4J52; -.
DR   PDBsum; 4J53; -.
DR   PDBsum; 4LKL; -.
DR   PDBsum; 4LKM; -.
DR   PDBsum; 4O56; -.
DR   PDBsum; 4O6W; -.
DR   PDBsum; 4O9W; -.
DR   PDBsum; 4RCP; -.
DR   PDBsum; 4WHH; -.
DR   PDBsum; 4WHK; -.
DR   PDBsum; 4WHL; -.
DR   PDBsum; 4X9R; -.
DR   PDBsum; 4X9V; -.
DR   PDBsum; 4X9W; -.
DR   PDBsum; 5J19; -.
DR   PDBsum; 5TA6; -.
DR   PDBsum; 5TA8; -.
DR   DisProt; DP00428; -.
DR   ProteinModelPortal; P53350; -.
DR   SMR; P53350; -.
DR   BioGrid; 111362; 232.
DR   DIP; DIP-29696N; -.
DR   IntAct; P53350; 165.
DR   MINT; MINT-86316; -.
DR   STRING; 9606.ENSP00000300093; -.
DR   BindingDB; P53350; -.
DR   ChEMBL; CHEMBL3024; -.
DR   GuidetoPHARMACOLOGY; 2168; -.
DR   iPTMnet; P53350; -.
DR   PhosphoSitePlus; P53350; -.
DR   BioMuta; PLK1; -.
DR   DMDM; 1709658; -.
DR   EPD; P53350; -.
DR   MaxQB; P53350; -.
DR   PaxDb; P53350; -.
DR   PeptideAtlas; P53350; -.
DR   PRIDE; P53350; -.
DR   DNASU; 5347; -.
DR   Ensembl; ENST00000300093; ENSP00000300093; ENSG00000166851.
DR   GeneID; 5347; -.
DR   KEGG; hsa:5347; -.
DR   UCSC; uc002dlz.2; human.
DR   CTD; 5347; -.
DR   DisGeNET; 5347; -.
DR   GeneCards; PLK1; -.
DR   HGNC; HGNC:9077; PLK1.
DR   HPA; HPA051638; -.
DR   HPA; HPA053229; -.
DR   MIM; 602098; gene.
DR   neXtProt; NX_P53350; -.
DR   OpenTargets; ENSG00000166851; -.
DR   PharmGKB; PA33410; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   eggNOG; ENOG410XQBP; LUCA.
DR   GeneTree; ENSGT00530000062954; -.
DR   HOGENOM; HOG000248546; -.
DR   HOVERGEN; HBG001843; -.
DR   InParanoid; P53350; -.
DR   KO; K06631; -.
DR   OMA; KRYMTEH; -.
DR   OrthoDB; EOG091G0D89; -.
DR   PhylomeDB; P53350; -.
DR   TreeFam; TF101089; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-162658; Golgi Cisternae Pericentriolar Stack Reorganization.
DR   Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   Reactome; R-HSA-176412; Phosphorylation of the APC/C.
DR   Reactome; R-HSA-176417; Phosphorylation of Emi1.
DR   Reactome; R-HSA-2299718; Condensation of Prophase Chromosomes.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-2980767; Activation of NIMA Kinases NEK9, NEK6, NEK7.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-68881; Mitotic Metaphase/Anaphase Transition.
DR   Reactome; R-HSA-68884; Mitotic Telophase/Cytokinesis.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; P53350; -.
DR   SIGNOR; P53350; -.
DR   ChiTaRS; PLK1; human.
DR   EvolutionaryTrace; P53350; -.
DR   GeneWiki; PLK1; -.
DR   GenomeRNAi; 5347; -.
DR   PRO; PR:P53350; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000166851; -.
DR   CleanEx; HS_PLK1; -.
DR   ExpressionAtlas; P53350; baseline and differential.
DR   Genevisible; P53350; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0000942; C:condensed nuclear chromosome outer kinetochore; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:BHF-UCL.
DR   GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IMP:CAFA.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IMP:CAFA.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; TAS:Reactome.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0051297; P:centrosome organization; IMP:UniProtKB.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0000910; P:cytokinesis; IDA:UniProtKB.
DR   GO; GO:0045184; P:establishment of protein localization; IMP:MGI.
DR   GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl.
DR   GO; GO:0031572; P:G2 DNA damage checkpoint; IDA:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0045143; P:homologous chromosome segregation; IEA:Ensembl.
DR   GO; GO:0001578; P:microtubule bundle formation; IDA:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; IDA:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   GO; GO:0000070; P:mitotic sister chromatid segregation; IMP:UniProtKB.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0051081; P:nuclear envelope disassembly; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; TAS:Reactome.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IDA:UniProtKB.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0051437; P:positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition; TAS:Reactome.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IMP:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB.
DR   GO; GO:0090435; P:protein localization to nuclear envelope; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; TAS:Reactome.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; IMP:BHF-UCL.
DR   GO; GO:1901673; P:regulation of mitotic spindle assembly; IDA:CACAO.
DR   GO; GO:0043393; P:regulation of protein binding; IMP:BHF-UCL.
DR   GO; GO:0051439; P:regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007062; P:sister chromatid cohesion; TAS:Reactome.
DR   GO; GO:0070194; P:synaptonemal complex disassembly; IEA:Ensembl.
DR   CDD; cd13118; POLO_box_1; 1.
DR   CDD; cd13117; POLO_box_2; 1.
DR   CDD; cd14187; STKc_PLK1; 1.
DR   Gene3D; 3.30.1120.30; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033702; PLK1_cat.
DR   InterPro; IPR033701; POLO_box_1.
DR   InterPro; IPR033695; POLO_box_2.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Centromere; Chromosome; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Isopeptide bond; Kinase; Kinetochore; Mitosis; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    603       Serine/threonine-protein kinase PLK1.
FT                                /FTId=PRO_0000086556.
FT   DOMAIN       53    305       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      417    480       POLO box 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   DOMAIN      515    584       POLO box 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   NP_BIND      59     67       ATP.
FT   NP_BIND     178    181       ATP.
FT   REGION      194    221       Activation loop.
FT   REGION      493    507       Linker.
FT   REGION      538    540       Important for interaction with
FT                                phosphorylated proteins. {ECO:0000250}.
FT   MOTIF       337    340       D-box that targets the protein for
FT                                proteasomal degradation in anaphase.
FT   ACT_SITE    176    176       Proton acceptor.
FT   BINDING      82     82       ATP.
FT   BINDING     131    131       ATP; via carbonyl oxygen.
FT   BINDING     194    194       ATP.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES       6      6       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     103    103       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     137    137       Phosphoserine.
FT                                {ECO:0000305|PubMed:12207013}.
FT   MOD_RES     210    210       Phosphothreonine; by AURKA.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:18477460,
FT                                ECO:0000269|PubMed:18615013}.
FT   MOD_RES     214    214       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     269    269       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     335    335       Phosphoserine.
FT                                {ECO:0000269|PubMed:12442251}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     450    450       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     498    498       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   CROSSLNK     19     19       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18662541}.
FT   CROSSLNK    492    492       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23455478}.
FT   VARIANT      12     12       R -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041018.
FT   VARIANT     261    261       L -> F (in dbSNP:rs35056440).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041019.
FT   VARIANT     297    297       N -> D (in dbSNP:rs16972799).
FT                                /FTId=VAR_051659.
FT   VARIANT     332    332       L -> V (in dbSNP:rs45489499).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041020.
FT   VARIANT     463    463       L -> H (in dbSNP:rs45569335).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041021.
FT   VARIANT     518    518       R -> H (in dbSNP:rs56027600).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041022.
FT   VARIANT     595    595       S -> L (in dbSNP:rs34001032).
FT                                /FTId=VAR_051660.
FT   VARIANT     599    599       R -> H (in dbSNP:rs34954545).
FT                                /FTId=VAR_051661.
FT   MUTAGEN      67     67       C->V: In analog-sensitive mutant;
FT                                enlarged catalytic pocket to accommodate
FT                                purine analogs; when associated with G-
FT                                130. {ECO:0000269|PubMed:19468302}.
FT   MUTAGEN      82     82       K->M: Loss of kinase activity. No effect
FT                                on S-phase progression.
FT                                {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:12447691,
FT                                ECO:0000269|PubMed:18174154,
FT                                ECO:0000269|PubMed:24018379}.
FT   MUTAGEN      82     82       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:18615013,
FT                                ECO:0000269|PubMed:19160488}.
FT   MUTAGEN     130    130       L->G: In analog-sensitive mutant;
FT                                enlarged catalytic pocket to accommodate
FT                                purine analogs; when associated with V-
FT                                67. {ECO:0000269|PubMed:19468302}.
FT   MUTAGEN     137    137       S->A: No change in activity. Increases
FT                                activity and restores recovery after DNA
FT                                damage checkpoint; when associated with
FT                                D-210. {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:18615013}.
FT   MUTAGEN     137    137       S->D: Increases activity. Results in a
FT                                block in G1/S.
FT                                {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:18615013}.
FT   MUTAGEN     176    176       D->N: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:18615013}.
FT   MUTAGEN     194    194       D->A: Does not interfere with FRY-
FT                                binding. {ECO:0000269|PubMed:22753416}.
FT   MUTAGEN     210    210       T->A: Abolishes activity. Abolishes
FT                                checkpoint recovery.
FT                                {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:12447691,
FT                                ECO:0000269|PubMed:17461553,
FT                                ECO:0000269|PubMed:18615013,
FT                                ECO:0000269|PubMed:19160488}.
FT   MUTAGEN     210    210       T->D: Increases activity and restores
FT                                recovery after DNA damage checkpoint.
FT                                {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:12447691,
FT                                ECO:0000269|PubMed:17461553,
FT                                ECO:0000269|PubMed:18615013,
FT                                ECO:0000269|PubMed:19160488}.
FT   MUTAGEN     210    210       T->V: Reduced catalytic activity, but no
FT                                effect on affinity for ATP.
FT                                {ECO:0000269|PubMed:12207013,
FT                                ECO:0000269|PubMed:12447691,
FT                                ECO:0000269|PubMed:17461553,
FT                                ECO:0000269|PubMed:18615013,
FT                                ECO:0000269|PubMed:19160488}.
FT   MUTAGEN     337    337       R->A: Interferes with ubiquitination and
FT                                subsequent proteasomal degradation in
FT                                anaphase; when associated with A-340.
FT                                {ECO:0000269|PubMed:14734534,
FT                                ECO:0000269|PubMed:18662541}.
FT   MUTAGEN     340    340       L->A: Interferes with ubiquitination and
FT                                subsequent proteasomal degradation in
FT                                anaphase; when associated with A-337.
FT                                {ECO:0000269|PubMed:14734534,
FT                                ECO:0000269|PubMed:18662541}.
FT   MUTAGEN     414    414       W->F: Abolishes interaction with CDC25C
FT                                and reduces centrosomal localization.
FT                                {ECO:0000269|PubMed:17307877}.
FT   MUTAGEN     414    414       W->F: No effect on centrosomal
FT                                localization, nor on S-phase progression;
FT                                when asscociated with A-427. Loss of
FT                                centrosomal localization and of S-phase
FT                                progression; when associated with A- 415
FT                                and A-427. {ECO:0000269|PubMed:24018379}.
FT   MUTAGEN     415    415       V->A: Loss of centrosomal localization
FT                                and of S-phase progression; when
FT                                associated with A- 414 and A-427.
FT                                {ECO:0000269|PubMed:24018379}.
FT   MUTAGEN     427    427       L->A: No effect on centrosomal
FT                                localization, nor on S-phase progression;
FT                                when associated with A-414. Loss of
FT                                centrosomal localization and of S-phase
FT                                progression; when associated with A- 414
FT                                and A-415. {ECO:0000269|PubMed:24018379}.
FT   MUTAGEN     492    492       K->R: Severe mitotic defects leading to
FT                                prometaphase delay. Increased
FT                                localization at kinetochores leading to
FT                                increased levels of phosphorylated BUBR1.
FT                                {ECO:0000269|PubMed:23455478}.
FT   MUTAGEN     538    538       H->A: In pincer mutant; loss of
FT                                centrosomal location and decreased
FT                                interaction with phosphorylated CDC25C
FT                                and BUB1; when associated with M-540.
FT                                {ECO:0000269|PubMed:14532005,
FT                                ECO:0000269|PubMed:16760428,
FT                                ECO:0000269|PubMed:18477460,
FT                                ECO:0000269|PubMed:19468302}.
FT   MUTAGEN     540    540       K->M: In pincer mutant; loss of
FT                                centrosomal location and decreased
FT                                interaction with phosphorylated CDC25C
FT                                and BUB1; when associated with A-538.
FT                                {ECO:0000269|PubMed:14532005,
FT                                ECO:0000269|PubMed:16760428,
FT                                ECO:0000269|PubMed:18477460,
FT                                ECO:0000269|PubMed:19468302}.
FT   CONFLICT      2      2       S -> T (in Ref. 1; AAA56634).
FT                                {ECO:0000305}.
FT   CONFLICT     11     11       A -> P (in Ref. 1; AAA56634).
FT                                {ECO:0000305}.
FT   CONFLICT     58     58       F -> L (in Ref. 1; AAA56634).
FT                                {ECO:0000305}.
FT   CONFLICT     60     60       G -> S (in Ref. 1; AAA56634).
FT                                {ECO:0000305}.
FT   CONFLICT     73     73       A -> V (in Ref. 2; AAA36659 and 7;
FT                                AAB36946). {ECO:0000305}.
FT   CONFLICT    123    123       N -> T (in Ref. 6; CAA62260).
FT                                {ECO:0000305}.
FT   CONFLICT    141    141       L -> P (in Ref. 4; CAA53536).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       G -> E (in Ref. 4; CAA53536).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       N -> G (in Ref. 2; AAA36659).
FT                                {ECO:0000305}.
FT   CONFLICT    495    495       A -> G (in Ref. 2; AAA36659).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       E -> Q (in Ref. 2; AAA36659).
FT                                {ECO:0000305}.
FT   STRAND       42     46       {ECO:0000244|PDB:2RKU}.
FT   TURN         47     50       {ECO:0000244|PDB:2RKU}.
FT   STRAND       51     62       {ECO:0000244|PDB:2RKU}.
FT   STRAND       65     72       {ECO:0000244|PDB:2RKU}.
FT   TURN         73     75       {ECO:0000244|PDB:2RKU}.
FT   STRAND       78     85       {ECO:0000244|PDB:2RKU}.
FT   HELIX        86     88       {ECO:0000244|PDB:2RKU}.
FT   HELIX        92    106       {ECO:0000244|PDB:2RKU}.
FT   STRAND      116    121       {ECO:0000244|PDB:2RKU}.
FT   STRAND      123    131       {ECO:0000244|PDB:2RKU}.
FT   HELIX       138    145       {ECO:0000244|PDB:2RKU}.
FT   HELIX       150    169       {ECO:0000244|PDB:2RKU}.
FT   HELIX       179    181       {ECO:0000244|PDB:2RKU}.
FT   STRAND      182    184       {ECO:0000244|PDB:2RKU}.
FT   STRAND      190    192       {ECO:0000244|PDB:2RKU}.
FT   HELIX       220    223       {ECO:0000244|PDB:2RKU}.
FT   STRAND      224    226       {ECO:0000244|PDB:2V5Q}.
FT   HELIX       231    246       {ECO:0000244|PDB:2RKU}.
FT   HELIX       256    264       {ECO:0000244|PDB:2RKU}.
FT   HELIX       276    285       {ECO:0000244|PDB:2RKU}.
FT   HELIX       290    292       {ECO:0000244|PDB:2RKU}.
FT   HELIX       296    301       {ECO:0000244|PDB:2RKU}.
FT   HELIX       303    306       {ECO:0000244|PDB:2RKU}.
FT   HELIX       316    319       {ECO:0000244|PDB:2RKU}.
FT   HELIX       367    370       {ECO:0000244|PDB:5J19}.
FT   HELIX       374    386       {ECO:0000244|PDB:4X9R}.
FT   HELIX       389    391       {ECO:0000244|PDB:4X9R}.
FT   STRAND      392    394       {ECO:0000244|PDB:3P34}.
FT   HELIX       397    400       {ECO:0000244|PDB:4X9R}.
FT   HELIX       403    405       {ECO:0000244|PDB:4X9R}.
FT   STRAND      411    417       {ECO:0000244|PDB:4X9R}.
FT   TURN        418    421       {ECO:0000244|PDB:4X9R}.
FT   STRAND      422    427       {ECO:0000244|PDB:4X9R}.
FT   STRAND      432    436       {ECO:0000244|PDB:4X9R}.
FT   STRAND      441    444       {ECO:0000244|PDB:4X9R}.
FT   STRAND      448    454       {ECO:0000244|PDB:4X9R}.
FT   STRAND      460    464       {ECO:0000244|PDB:4X9R}.
FT   TURN        465    467       {ECO:0000244|PDB:3Q1I}.
FT   HELIX       470    472       {ECO:0000244|PDB:4X9R}.
FT   HELIX       473    488       {ECO:0000244|PDB:4X9R}.
FT   TURN        493    496       {ECO:0000244|PDB:4X9R}.
FT   TURN        503    505       {ECO:0000244|PDB:3P34}.
FT   STRAND      511    516       {ECO:0000244|PDB:4X9R}.
FT   STRAND      518    525       {ECO:0000244|PDB:4X9R}.
FT   TURN        526    528       {ECO:0000244|PDB:4WHL}.
FT   STRAND      530    534       {ECO:0000244|PDB:4X9R}.
FT   TURN        535    537       {ECO:0000244|PDB:4X9R}.
FT   STRAND      540    544       {ECO:0000244|PDB:4X9R}.
FT   TURN        545    548       {ECO:0000244|PDB:4X9R}.
FT   STRAND      549    553       {ECO:0000244|PDB:4X9R}.
FT   STRAND      559    563       {ECO:0000244|PDB:4X9R}.
FT   HELIX       564    570       {ECO:0000244|PDB:4X9R}.
FT   HELIX       574    591       {ECO:0000244|PDB:4X9R}.
FT   STRAND      593    595       {ECO:0000244|PDB:4O56}.
FT   STRAND      598    602       {ECO:0000244|PDB:4O56}.
SQ   SEQUENCE   603 AA;  68255 MW;  178C2F13C10E8206 CRC64;
     MSAAVTAGKL ARAPADPGKA GVPGVAAPGA PAAAPPAKEI PEVLVDPRSR RRYVRGRFLG
     KGGFAKCFEI SDADTKEVFA GKIVPKSLLL KPHQREKMSM EISIHRSLAH QHVVGFHGFF
     EDNDFVFVVL ELCRRRSLLE LHKRRKALTE PEARYYLRQI VLGCQYLHRN RVIHRDLKLG
     NLFLNEDLEV KIGDFGLATK VEYDGERKKT LCGTPNYIAP EVLSKKGHSF EVDVWSIGCI
     MYTLLVGKPP FETSCLKETY LRIKKNEYSI PKHINPVAAS LIQKMLQTDP TARPTINELL
     NDEFFTSGYI PARLPITCLT IPPRFSIAPS SLDPSNRKPL TVLNKGLENP LPERPREKEE
     PVVRETGEVV DCHLSDMLQQ LHSVNASKPS ERGLVRQEEA EDPACIPIFW VSKWVDYSDK
     YGLGYQLCDN SVGVLFNDST RLILYNDGDS LQYIERDGTE SYLTVSSHPN SLMKKITLLK
     YFRNYMSEHL LKAGANITPR EGDELARLPY LRTWFRTRSA IILHLSNGSV QINFFQDHTK
     LILCPLMAAV TYIDEKRDFR TYRLSLLEEY GCCKELASRL RYARTMVDKL LSSRSASNRL
     KAS
//
